Search results for ''
Selection in the Best of the Liver Meeting 2021
ENYO Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor’s key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.
EASL – International Liver Congress 2022
22-26 June, 2022
London, UK.
ENYO Pharma will attend the EASL International Liver Congress at London in April 2022.
International Workshop on HBV Cure 2021 (Sponsorship)
Virtual Event
9-10 November 2021
ENYO Pharma sponsors and attends the International Workshop on HBV Cure 2021 organized by Virology Education in close collaboration with the Toronto Centre for Liver Disease and chaired by Drs. Harry Janssen and Adam Gehring, the International Workshop on HBV Cure.
https://academicmedicaleducation.com/hbv-cure-2021/
ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
Lyon, France. November 3rd, 2021 – ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.
Etienne Morel’s talk at ITMO Cell Biology (Aviesan)
Etienne Morel, collaborator of ENYO Pharma, gave a talk describing the results of our collaboration entitled: “Mitochondrial morphodynamics and ER-mitochondria membrane crosstalk in antiviral innate immunity” at “ITMO Cell biology, development and evolution” event organized by Aviesan on October the 6th, 2021.
Latest Press Release 